In non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), METTL3-mediated m6A modification enhances autophagy and mitophagy, contributing to gefitinib resistance and chemoresistance, respectively [174, 175]. This evidence concerns the gene METTL3 and non-small cell lung carcinoma.